Financial Report
1 January - 30 June (unaudited)
|
kEUR |
Note |
H1 2022 |
H1 2021 |
|
|
|
|
|
|
Revenue |
4 |
133,656 |
135,136 |
|
Other operating income |
|
954 |
2,936 |
|
Total income |
|
134,610 |
138,072 |
|
|
|
|
|
|
Cost of sales |
|
-96,776 |
-86,839 |
|
Gross profit |
|
37,834 |
51,233 |
|
|
|
|
|
|
Marketing and sales expenses |
|
-2,589 |
-2,133 |
|
Research expenses |
|
-656 |
-696 |
|
General and administrative expenses |
5 |
-19,107 |
-17,601 |
|
Total operating expenses |
|
-22,352 |
-20,430 |
|
|
|
|
|
|
Operating result (EBIT) |
|
15,482 |
30,803 |
|
|
|
|
|
|
Financial income |
|
4 |
6 |
|
Financial expenses |
|
-2,645 |
-1,282 |
|
Total financial result |
|
-2,641 |
-1,276 |
|
|
|
|
|
|
Result before income taxes |
|
12,841 |
29,527 |
|
|
|
|
|
|
Income tax charges |
|
-2,594 |
-4,904 |
|
Result for the period |
|
10,247 |
24,623 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
10,247 |
24,623 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
8 |
0.31 |
0.79 |
|
Earnings per share in EUR, diluted |
8 |
0.31 |
0.79 |